文献速递儿科与产科急症重症综合管理与镇静镇痛

血小板输注与极早产儿死亡或神经发育损害的关系

Platelet Transfusion and Death or Neurodevelopmental Impairment in Children Born Extremely Preterm.
PubMed 文献 · JAMA Netw Open · 2024-01-02
一句话结论极早产儿住院期间接受血小板输注者2岁矫正年龄死亡或严重神经发育损害风险升高(OR 2.43),但可能存在适应症残余混杂。

该研究为Preterm Erythropoietin Neuroprotection Trial的观察性队列二次分析,纳入美国30个新生儿重症监护病房819例24至27周极早产儿,评估新生儿重症监护病房住院期间任何血小板输注与2岁矫正年龄死亡或严重神经发育损害(严重脑瘫或BSID-III复合运动或认知评分低于均值2个标准差)的关联。245例(30.0%)接受至少1次血小板输注,暴露组主要结局发生率46.5%,非暴露组13.9%,校正倾向评分、出生胎龄和试验治疗组后OR为2.43(95%CI 1.24-4.76)。死亡和严重神经发育损害各组分方向与复合结局一致。作者认为血小板输注可能与死亡或严重神经发育损害风险升高相关,但不能排除适应症残余混杂。

要点

  • 819例24至27周极早产儿中,245例(30.0%)住院期间接受至少1次血小板输注,暴露组死亡或严重神经发育损害发生率46.5%,非暴露组13.9%。
  • 校正倾向评分、出生胎龄和试验治疗组后,血小板输注与2岁矫正年龄死亡或严重神经发育损害相关,OR 2.43(95%CI 1.24-4.76)。
  • 死亡和严重神经发育损害各组分方向与复合结局一致,支持整体关联方向。
  • 作者认为极早产儿血小板输注可能与死亡或严重神经发育损害风险升高相关,但不能排除适应症残余混杂。

适用人群与场景

  • 美国30个新生儿重症监护病房中出生胎龄24至27周的极早产儿,且有记录的结局(死亡或神经发育评估)。

诊断标准与关键阈值

  • 严重神经发育损害定义:存在严重脑瘫,或BSID-III复合运动或认知评分低于均值2个标准差。
  • 主要复合结局为2岁矫正年龄时死亡或严重神经发育损害,采用BSID-III和粗大运动功能分类系统评估。

研究设计与关键结果

  • 研究类型:观察性队列研究及Preterm Erythropoietin Neuroprotection Trial(随机、安慰剂对照的促红细胞生成素神经保护试验)的二次分析,美国30个新生儿重症监护病房,2013年12月1日至2016年9月31日。
  • 分析纳入819例极早产儿(429例[52.4%]男性;平均[SD]胎龄25.5[1.1]周),245例(30.0%)在初次住院期间接受至少1次血小板输注。
  • 主要结局在血小板输注暴露组发生率为46.5%(114/245),非暴露组为13.9%(80/574),校正倾向评分、出生胎龄和试验治疗组后OR为2.43(95%CI 1.24-4.76)。
  • 死亡和严重神经发育损害各组分方向与整体复合结局一致。
  • 分析于2023年4月进行。

证据类型、等级与局限

  • 证据类型:观察性队列研究及随机对照试验的二次分析。
  • 局限:不能排除适应症导致的残余混杂。

对床旁实践的改变

  • 作者认为,极早产儿血小板输注可能与2岁矫正年龄死亡或严重神经发育损害风险升高相关,但不能排除适应症残余混杂。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Infants born extremely preterm receive transfusions at higher platelet count thresholds than older children and adults due to concerns for intracranial hemorrhage. A recent randomized trial comparing 2 platelet transfusion thresholds showed the higher threshold was associated with increased risk of long-term adverse neurodevelopmental outcomes.

OBJECTIVE: To evaluate the association of platelet transfusion exposure with death and severe neurodevelopmental impairment (NDI) at 2 years' corrected age in a cohort of infants born extremely preterm.

DESIGN, SETTING, AND PARTICIPANTS: An observational cohort study and secondary analysis of the Preterm Erythropoietin Neuroprotection Trial, a randomized, placebo-controlled clinical trial of erythropoietin neuroprotection in neonates born extremely preterm, was conducted in 30 neonatal intensive care units in the US from December 1, 2013, to September 31, 2016. This analysis included 819 infants born extremely preterm at 24 to 27 completed weeks of gestation who had a documented outcome (death or neurodevelopmental assessment). Analysis was performed in April 2023.

EXPOSURES: Any platelet transfusion during neonatal intensive care unit hospitalization.

MAIN OUTCOMES AND MEASURES: The primary composite outcome was death or severe NDI evaluated at 2 years' corrected age using the Bayley Scales of Infant Development-Third Edition (BSID-III) and the Gross Motor Function Classification System and was defined as the presence of severe cerebral palsy or a BSID-III composite motor or cognitive score 2 SDs below the mean. Confounding by indication for platelet transfusion was addressed with covariate adjustment and propensity score methods.

RESULTS: Of the 819 infants included in the analysis (429 [52.4%] male; mean [SD] gestational age, 25.5 [1.1] weeks), 245 (30.0%) received at least 1 platelet transfusion during their initial hospitalization. The primary outcome occurred in 46.5% (114 of 245) of infants exposed to a platelet transfusion and 13.9% (80 of 574) of nonexposed infants with a corresponding odds ratio of 2.43 (95% CI, 1.24-4.76), adjusted for propensity score, gestational age at birth, and trial treatment group. The individual components of death and severe NDI were directionally consistent with the overall composite outcome.

CONCLUSIONS AND RELEVANCE: The findings of this study suggest that platelet transfusion in infants born extremely preterm may be associated with an increased risk of death or severe NDI at 2 years' corrected age, although the possibility of residual confounding by indication cannot be excluded.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Davenport PE, Wood TR, Heagerty PJ, et al. Platelet Transfusion and Death or Neurodevelopmental Impairment in Children Born Extremely Preterm. JAMA Netw Open. 2024. PMID: 38261320. doi:10.1001/jamanetworkopen.2023.52394

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。